| Literature DB >> 31126334 |
Maria Llop1,2, Valeria Rios Rodriguez1, Imke Redeker1,3, Joachim Sieper1, Hildrun Haibel1, Martin Rudwaleit1,4, Denis Poddubnyy5,6.
Abstract
BACKGROUND: To evaluate the performance of the extended modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) incorporating information from anteroposterior (AP) lumbar radiographs as compared to the conventional mSASSS in detection of radiographic spinal progression in patients with axial spondyloarthritis (axSpA)Entities:
Keywords: Axial spondyloarthritis; Radiographic spinal progression; Radiographs; X-rays; mSASSS
Mesh:
Year: 2019 PMID: 31126334 PMCID: PMC6533656 DOI: 10.1186/s13075-019-1913-z
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Baseline demographic and clinical characteristics of the included patients with axial spondyloarthritis
| Parameter | Non-radiographic axial SpA ( | Radiographic axial SpA ( | All patients ( |
|---|---|---|---|
| Age, mean ± SD years | 38.7 ± 9.9 | 36.1 ± 11.0 | 37.3 ± 10.6 |
| Symptom duration, mean ± SD years | 3.1 ± 2.2 | 5.0 ± 2.8 | 4.2 ± 2.7 |
| Duration since diagnosis, mean ± SD years | 1.0 ± 1.3 | 2.0 ± 2.0 | 1.5 ± 1.8 |
| Male sex, | 32 (33.7) | 75 (65.2) | 107 (51.0) |
| HLA-B27 positive, | 69 (73.4) | 97 (84.3) | 166 (79.4) |
| Peripheral arthritis, | 16 (16.8) | 15 (13.0) | 31 (14.8) |
| Enthesitis†, | 23 (24.2) | 23 (20.0) | 46 (21.9) |
| Uveitis, ever, | 15 (15.8) | 27 (23.5) | 42 (20.0) |
| Psoriasis, ever, | 11 (11.6) | 17 (14.8) | 28 (13.3) |
| Inflammatory bowel disease, ever, | 1 (1.1) | 3 (2.6) | 4 (1.9) |
| Family history for SpA, | 16 (16.8) | 19 (16.5) | 35 (16.7) |
| BASDAI, mean ± SD, 0–10 | 4.2 ± 2.0 | 3.8 ± 2.2 | 4.0 ± 2.1 |
| BASFI, mean ± SD, 0–10 | 2.8 ± 2.2 | 3.0 ± 2.4 | 2.9 ± 2.3 |
| Treatment with NSAIDs, | 65 (68.4) | 78 (67.8) | 143 (68.1) |
| Treatment with csDMARDs, | 26 (28.6) | 35 (32.4) | 61 (30.7) |
| Treatment with systemic steroids, | 6 (6.7) | 6 (5.6) | 12 (6.1) |
| Treatment with a TNFα blocker, | 1 (1.1) | 4 (3.7) | 5 (2.5) |
| Smoking, current, | 24 (25.3) | 39 (33.9) | 63 (30.0) |
† Twelve enthesitis sites of the lower limbs plus optional symptomatic sites elsewhere were assessed
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, NSAIDs nonsteroidal antiinflammatory drugs, SD standard deviation, SpA spondyloarthritis, TNFα tumor necrosis factor α
Status and change scores of mSASSS and extended mSASSS
| All patients ( | Radiographic axial SpA ( | Non-radiographic axial SpA ( | ||||
|---|---|---|---|---|---|---|
| mSASSS | Extended mSASSS | mSASSS | Extended mSASSS | mSASSS | Extended mSASSS | |
| Status score at baseline, mean ± SD | 4.2 ± 8.3 | 8.6 ± 18.0 | 5.9 ± 10.3 | 12.8 ± 22.5 | 2.3 ± 4.2 | 3.5 ± 7.4 |
| Status score at year 2, mean ± SD | 5.0 ± 9.6 | 9.8 ± 20.0 | 6.8 ± 11.7 | 14.5 ± 24.9 | 2.8 ± 5.3 | 4.1 ± 8.9 |
| Change score, mean ± SD | 0.7 ± 2.3 | 1.2 ± 3.7 | 1.0 ± 2.8 | 1.7 ± 4.6 | 0.5 ± 1.6 | 0.6 ± 2.2 |
| Smallest detectable change | 4.1 | 6.4 | 4.7 | 7.5 | 3.3 | 4.6 |
| Change score ≥ smallest detectable change, | 14 (6.7) | 12 (5.7) | 7 (6.1) | 8 (7.0) | 4 (4.2) | 6 (6.3) |
| Presence of syndesmophytes at baseline, | 48 (22.9) | 64 (30.5) | 35 (30.4) | 48 (41.7) | 13 (13.7) | 16 (16.8) |
| Presence of syndesmophytes at year 2, | 50 (23.8) | 65 (31.0) | 36 (31.3) | 50 (43.5) | 14 (14.7) | 15 (15.8) |
| Total number of syndesmophytes at baseline, mean ± SD | 0.9 ± 2.6 | 1.9 ± 5.2 | 1.5 ± 3.3 | 3.2 ± 6.6 | 0.3 ± 1.1 | 0.5 ± 1.9 |
| Total number of syndesmophytes at year 2, mean ± SD | 1.1 ± 3.1 | 2.2 ± 6.0 | 1.7 ± 3.8 | 3.5 ± 7.6 | 0.4 ± 1.4 | 0.6 ± 2.4 |
| Change score ≥ 2 points after 2 years, | 30 (14.3) | 44 (21.0) | 23 (20.0) | 35 (30.4) | 7 (7.4) | 9 (9.5) |
| Development of new syndesmophytes after 2 years, | 16 (7.6) | 20 (9.5) | 13 (11.3) | 17 (14.8) | 3 (3.2) | 3 (3.2) |
| Development of new /growth of existing syndesmophytes after 2 years, | 18 (8.6) | 23 (11.0) | 15 (13.0) | 20 (17.4) | 3 (3.2) | 3 (3.2) |
mSASSS modified Stoke Ankylosing Spondylitis Spine Score, SD standard deviation
Status and change scores of the components of the mSASSS and the extended mSASSS
| Cervical spine lateral view | Lumbar spine lateral view | Lumbar spine AP view | |
|---|---|---|---|
| Change score ≥ 2 points after 2 years, | 29 (13.8) | 18 (8.6) | 25 (11.9) |
| Total number of syndesmophytes at baseline, mean ± SD | 0.5 ± 1.6 | 0.4 ± 1.5 | 1.0 ± 3.0 |
| Total number of syndesmophytes at year 2, mean ± SD | 0.6 ± 1.7 | 0.6 ± 1.8 | 1.1 ± 3.3 |
| Development of new syndesmophytes after 2 years, | 8 (3.8) | 8 (3.8) | 9 (4.4) |
| Development of new/growth of existing syndesmophytes after 2 years, | 8 (3.8) | 10 (4.8) | 10 (4.8) |
mSASSS includes scores of the cervical and lumbar lateral views; extended mSASSS includes additionally the lumbar spine AP view
AP anteroposterior, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, SD standard deviation
Inter-observer reliability of the components of the mSASSS and the extended mSASSS
| Cervical spine lateral view | Lumbar spine lateral view | Lumbar spine AP view | |
|---|---|---|---|
| ICC for the status score at baseline | 0.91 (0.88, 0.93) | 0.91 (0.88, 0.93) | 0.86 (0.83, 0.90) |
| ICC for the status score at year 2 | 0.86 (0.82, 0.89) | 0.92 (0.90, 0.94) | 0.88 (0.84, 0.90) |
| ICC for the change score | 0.49 (0.39, 0.59) | 0.43 (0.32, 0.54) | 0.30 (0.19, 0.44) |
| Kappa for the change score ≥ 2 points after 2 years | 0.13 (− 0.04, 0.29) | 0.38 (0.18, 0.57) | 0.36 (0.18, 0.54) |
| Kappa for the development of new syndesmophytes after 2 years | 0.38 (0.20, 0.55) | 0.59 (0.42, 0.77) | 0.40 (0.24, 0.57) |
| Kappa for the development of new/growth of existing syndesmophytes after 2 years | 0.34 (0.17, 0.52) | 0.62 (0.46, 0.79) | 0.48 (0.32, 0.64) |
Data are presented as intraclass correlation coefficient (ICC) and Cohen’s kappa coefficient to measure the inter-observer reliability for continuous and categorical variables, respectively, with a 95% CI
AP anteroposterior, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, CI confidence interval, ICC intraclass correlation coefficient
Inter-observer reliability of the mSASSS and the extended mSASSS, expressed in variance components
| Status score at baseline | Status score at year 2 | Change score | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Residual variance component | Observer variance component | Patient variance component | Residual variance component | Observer variance component | Patient variance component | Residual variance component | Observer variance component | Patient variance component | |
| mSASSS | 7.45 | 0.03 | 92.52 | 7.95 | 0.05 | 92.00 | 57.42 | 0.00 | 42.58 |
| Extended mSASSS | 7.28 | 0.01 | 92.71 | 6.67 | 0.00 | 93.33 | 54.99 | 0.00 | 45.01 |
mSASSS modified Stoke Ankylosing Spondylitis Spine Score
Inter-observer reliability of the components of the mSASSS and the extended mSASSS, expressed in variance components
| Cervical spine lateral view | Lumbar spine lateral view | Lumbar spine AP view | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Residual variance component | Observer variance component | Patient variance component | Residual variance component | Observer variance component | Patient variance component | Residual variance component | Observer variance component | Patient variance component | |
| Status score at baseline | 8.87 | 0.06 | 91.07 | 9.05 | 0.00 | 90.95 | 13.23 | 0.22 | 86.55 |
| Status score at year 2 | 13.71 | 0.19 | 86.10 | 7.49 | 0.00 | 92.51 | 12.14 | 0.13 | 87.73 |
| Change score | 50.49 | 0.18 | 49.33 | 57.11 | 0.00 | 42.89 | 69.54 | 0.00 | 30.46 |
AP anteroposterior, mSASSS modified Stoke Ankylosing Spondylitis Spine Score
Fig. 1Bland and Altman plots for mSASSS (a) and extended mSASSS (b)
Association between mSASSS or extended mSASSS score with BASFI or BASMI at baseline in the linear regression analysis
| Univariable analysis | Multivariable model 1* | Multivariable model 2* | |
|---|---|---|---|
| Outcome: BASFI | |||
| mSASSS | 0.046 (0.008, 0.083) | 0.033 (0.010, 0.056) | – |
| Extended mSASSS | 0.021 (0.003, 0.038) | – | 0.014 (0.004, 0.025) |
| Outcome: BASMI | |||
| mSASSS | 0.093 (0.068, 0.117) | 0.082 (0.059, 0.106) | – |
| Extended mSASSS | 0.045 (0.034, 0.056) | – | 0.040 (0.029, 0.050) |
*Adjusted for BASDAI and CRP at baseline
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI the Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, mSASSS modified Stoke Ankylosing Spondylitis Spine Score